Clostridium difficile associated-infections;Infections à clostridium difficile

Medecine/Sciences

Volumn 26, Issue 2, 2010, Pages 153-158

  Eckert, Catherine ^a   Barbut, Frédéric ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACILLUS (BACTERIUM); BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE;

EID: 77749311711     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2010262153     Document Type: Review

References (21)

1. Janoir C, Pechine S, Grosdidier C, et al. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol 2007;189:7174-80.
2. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009;458:1176-9.
3. Jank T, Aktories K. Structure and mode of action of clostridial glycosylating toxins: the ABCD model. Trends Microbiol 2008;16:222-9.
4. Dupuy B, Govind R, Antunes A, et al. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008;57:685-9.
5. Popoff MR, Rubin EJ, Gill DM, et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988;56:2299-306.
6. Carter GP, Lyras D, Allen DL, et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 2007;189:7290-301.
7. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP- ribosyltransferase)-producing strains. J Med Microbiol 2005;54:181-5.
8. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7.
9. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93.
10. Barbut F, Beaugerie L, Petit JC. Clostridium difficile et pathologie digestive. EMC (Elsevier Masson Paris), Maladies infectieuses 2008;8-038-H-20.
11. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.
12. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile- associated disease in North America and Europe. Clin Microbiol Infect 2006;12 Suppl 6:2-18.
13. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
14. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;62:388-96.
15. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003;17:905-12.
16. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70.
17. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1): S12-8.
18. Barbut F, Braun M, Burghoffer B, et al. Rapid diagnosis of toxigenic strains of Clostridium difficile in diarrheal stools by real-time PCR. 1 Clin Microbiol 2009;47:1276-7.
19. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1): S32-42.
20. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
21. McFarland LV. Renewed interest in a difficult disease. Clostridium difficile infections: epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35.